FIELD: medicine.
SUBSTANCE: group of inventions relates to a method for the treatment of cancer, a method for reducing the size of tumor, a method for increasing survivability of a subject having cancer, a method for increasing an immune response against tumor, a method for the treatment of an autoimmune disease, and a method for weakening an inflammatory response in a subject who needs it, including injection to a subject of effective amount of a siglek-15 modulator, where the modulator reduces expression and/or activity of siglek-15 in a subject, where the modulator contains an antagonistic antibody to siglek-15 or its antigen-binding fragment and/or a recombinant fused protein of siglek-15.
EFFECT: group of inventions provides for the effective treatment of cancer, reduction in the size of tumor, increase in survivability, increase in an immune response against tumor, autoimmune disease, weakening of an inflammatory response.
44 cl, 27 dwg, 18 ex
| Title | Year | Author | Number |
|---|---|---|---|
| GLYCAN-DEPENDENT IMMUNOTHERAPY MOLECULES | 2016 |
|
RU2754661C2 |
| COMPOSITIONS AND METHODS FOR MODULATING THE TRANSMISSION OF A LAIR SIGNAL | 2017 |
|
RU2757394C2 |
| FGFR2 INHIBITORS SEPARATELY OR IN COMBINATION WITH IMMUNOSTIMULATING AGENTS IN CANCER TREATMENT | 2016 |
|
RU2745707C2 |
| COMPOSITIONS AND METHODS FOR IMMUNOTHERAPY | 2013 |
|
RU2729401C2 |
| METHODS FOR PRODUCING CELLS EXPRESSING CHIMERIC ANTIGEN RECEPTOR | 2015 |
|
RU2751362C2 |
| CSF1R-BASED CHIMERIC PROTEINS | 2018 |
|
RU2792239C2 |
| ANTIBODIES AGAINST SIGLEC-15 AND THEIR APPLICATION METHODS | 2017 |
|
RU2759334C2 |
| MESOTHELINIC CAR RECEPTORS AND USE THEREOF | 2020 |
|
RU2822193C2 |
| VECTOR, CO-EXPRESSING MOLECULES FOR VACCINATION AND COSTIMULATORY MOLECULES | 2016 |
|
RU2714157C2 |
| BIFUNCTIONAL PROTEINS COMBINING CHECKPOINT BLOCKADE FOR TARGETED THERAPY | 2019 |
|
RU2756899C1 |
